BIOMAT Database Logo BIOMAT Database Logo

Repurposing FDA-approved drugs for SARS-CoV-2 through an ELISA-based screening for the inhibition of RBD/ACE2 interaction. 2021

Wenyu Fu, and Yujianan Chen, and Kaidi Wang, and Aubryanna Hettinghouse, and Wenhuo Hu, and Jing-Quan Wang, and Zi-Ning Lei, and Zhe-Sheng Chen, and Kenneth A Stapleford, and Chuan-Ju Liu
Department of Orthopaedic Surgery, New York University Medical Center, 301 East 17th Street, New York, NY, 10003, USA.

UI MeSH Term Description Entries
D004364 Pharmaceutical Preparations Drugs intended for human or veterinary use, presented in their finished dosage form. Included here are materials used in the preparation and/or formulation of the finished dosage form. Drug,Drugs,Pharmaceutical,Pharmaceutical Preparation,Pharmaceutical Product,Pharmaceutic Preparations,Pharmaceutical Products,Pharmaceuticals,Preparations, Pharmaceutical,Preparation, Pharmaceutical,Preparations, Pharmaceutic,Product, Pharmaceutical,Products, Pharmaceutical
D004797 Enzyme-Linked Immunosorbent Assay An immunoassay utilizing an antibody labeled with an enzyme marker such as horseradish peroxidase. While either the enzyme or the antibody is bound to an immunosorbent substrate, they both retain their biologic activity; the change in enzyme activity as a result of the enzyme-antibody-antigen reaction is proportional to the concentration of the antigen and can be measured spectrophotometrically or with the naked eye. Many variations of the method have been developed. ELISA,Assay, Enzyme-Linked Immunosorbent,Assays, Enzyme-Linked Immunosorbent,Enzyme Linked Immunosorbent Assay,Enzyme-Linked Immunosorbent Assays,Immunosorbent Assay, Enzyme-Linked,Immunosorbent Assays, Enzyme-Linked
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000085962 Angiotensin-Converting Enzyme 2 A transmembrane glycoprotein with an extracellular catalytic domain which functions as a carboxypeptidase. It cleaves a single C-terminal residue from a distinct range of substrates. The catalytic efficiency is 400-fold higher with ANGIOTENSIN II as a substrate than with ANGIOTENSIN I. Angiotensin-converting enzyme 2 is also is a functional receptor for the spike glycoprotein (SPIKE PROTEIN, CORONAVIRUS) of the CORONAVIRUSES SARS-COV, SARS-COV2, and HCOV-NL63. ACE-Related Carboxypeptidase,ACE2 Angiotensin-Converting Enzyme Protein 2,ACE2 Enzyme,ACE2 Protein,Angiotensin Converting Enzyme 2,Angiotensin-Converting Enzyme-Related Carboxypeptidase,ACE Related Carboxypeptidase,ACE2 Angiotensin Converting Enzyme Protein 2,Angiotensin Converting Enzyme Related Carboxypeptidase,Carboxypeptidase, ACE-Related,Carboxypeptidase, Angiotensin-Converting Enzyme-Related
D000086382 COVID-19 A viral disorder generally characterized by high FEVER; COUGH; DYSPNEA; CHILLS; PERSISTENT TREMOR; MUSCLE PAIN; HEADACHE; SORE THROAT; a new loss of taste and/or smell (see AGEUSIA and ANOSMIA) and other symptoms of a VIRAL PNEUMONIA. In severe cases, a myriad of coagulopathy associated symptoms often correlating with COVID-19 severity is seen (e.g., BLOOD COAGULATION; THROMBOSIS; ACUTE RESPIRATORY DISTRESS SYNDROME; SEIZURES; HEART ATTACK; STROKE; multiple CEREBRAL INFARCTIONS; KIDNEY FAILURE; catastrophic ANTIPHOSPHOLIPID ANTIBODY SYNDROME and/or DISSEMINATED INTRAVASCULAR COAGULATION). In younger patients, rare inflammatory syndromes are sometimes associated with COVID-19 (e.g., atypical KAWASAKI SYNDROME; TOXIC SHOCK SYNDROME; pediatric multisystem inflammatory disease; and CYTOKINE STORM SYNDROME). A coronavirus, SARS-CoV-2, in the genus BETACORONAVIRUS is the causative agent. 2019 Novel Coronavirus Disease,2019 Novel Coronavirus Infection,2019-nCoV Disease,2019-nCoV Infection,COVID-19 Pandemic,COVID-19 Pandemics,COVID-19 Virus Disease,COVID-19 Virus Infection,Coronavirus Disease 2019,Coronavirus Disease-19,SARS Coronavirus 2 Infection,SARS-CoV-2 Infection,Severe Acute Respiratory Syndrome Coronavirus 2 Infection,COVID19,2019 nCoV Disease,2019 nCoV Infection,2019-nCoV Diseases,2019-nCoV Infections,COVID 19,COVID 19 Pandemic,COVID 19 Virus Disease,COVID 19 Virus Infection,COVID-19 Virus Diseases,COVID-19 Virus Infections,Coronavirus Disease 19,Disease 2019, Coronavirus,Disease, 2019-nCoV,Disease, COVID-19 Virus,Infection, 2019-nCoV,Infection, COVID-19 Virus,Infection, SARS-CoV-2,Pandemic, COVID-19,SARS CoV 2 Infection,SARS-CoV-2 Infections,Virus Disease, COVID-19,Virus Infection, COVID-19
D000086402 SARS-CoV-2 A species of BETACORONAVIRUS causing atypical respiratory disease (COVID-19) in humans. The organism was first identified in 2019 in Wuhan, China. The natural host is the Chinese intermediate horseshoe bat, RHINOLOPHUS affinis. 2019 Novel Coronavirus,COVID-19 Virus,COVID19 Virus,Coronavirus Disease 2019 Virus,SARS Coronavirus 2,SARS-CoV-2 Virus,Severe Acute Respiratory Syndrome Coronavirus 2,Wuhan Coronavirus,Wuhan Seafood Market Pneumonia Virus,2019-nCoV,2019 Novel Coronaviruses,COVID 19 Virus,COVID-19 Viruses,COVID19 Viruses,Coronavirus 2, SARS,Coronavirus, 2019 Novel,Coronavirus, Wuhan,Novel Coronavirus, 2019,SARS CoV 2 Virus,SARS-CoV-2 Viruses,Virus, COVID-19,Virus, COVID19,Virus, SARS-CoV-2,Viruses, COVID19
D058492 Drug Repositioning The deliberate and methodical practice of finding new applications for existing drugs. Drug Repurposing,Drug Rescue,Repositioning, Drug,Repurposing, Drug,Rescue, Drug

Related Publications

Wenyu Fu, and Yujianan Chen, and Kaidi Wang, and Aubryanna Hettinghouse, and Wenhuo Hu, and Jing-Quan Wang, and Zi-Ning Lei, and Zhe-Sheng Chen, and Kenneth A Stapleford, and Chuan-Ju Liu
Potential SARS-CoV-2 protease Mpro inhibitors: repurposing FDA-approved drugs.
February 2021, Physical biology,
Wenyu Fu, and Yujianan Chen, and Kaidi Wang, and Aubryanna Hettinghouse, and Wenhuo Hu, and Jing-Quan Wang, and Zi-Ning Lei, and Zhe-Sheng Chen, and Kenneth A Stapleford, and Chuan-Ju Liu
Repurposing of the approved small molecule drugs in order to inhibit SARS-CoV-2 S protein and human ACE2 interaction through virtual screening approaches.
February 2022, Journal of biomolecular structure & dynamics,
Wenyu Fu, and Yujianan Chen, and Kaidi Wang, and Aubryanna Hettinghouse, and Wenhuo Hu, and Jing-Quan Wang, and Zi-Ning Lei, and Zhe-Sheng Chen, and Kenneth A Stapleford, and Chuan-Ju Liu
Repurposing Screens of FDA-Approved Drugs Identify 29 Inhibitors of SARS-CoV-2.
December 2020, Journal of microbiology and biotechnology,
Wenyu Fu, and Yujianan Chen, and Kaidi Wang, and Aubryanna Hettinghouse, and Wenhuo Hu, and Jing-Quan Wang, and Zi-Ning Lei, and Zhe-Sheng Chen, and Kenneth A Stapleford, and Chuan-Ju Liu
Pharmacophore-based approaches in the rational repurposing technique for FDA approved drugs targeting SARS-CoV-2 Mpro.
November 2020, RSC advances,
Wenyu Fu, and Yujianan Chen, and Kaidi Wang, and Aubryanna Hettinghouse, and Wenhuo Hu, and Jing-Quan Wang, and Zi-Ning Lei, and Zhe-Sheng Chen, and Kenneth A Stapleford, and Chuan-Ju Liu
Repurposing FDA-approved drugs against multiple proteins of SARS-CoV-2: An in silico study.
September 2021, Scientific African,
Wenyu Fu, and Yujianan Chen, and Kaidi Wang, and Aubryanna Hettinghouse, and Wenhuo Hu, and Jing-Quan Wang, and Zi-Ning Lei, and Zhe-Sheng Chen, and Kenneth A Stapleford, and Chuan-Ju Liu
Correction: Pharmacophore-based approaches in the rational repurposing technique for FDA approved drugs targeting SARS-CoV-2 Mpro.
November 2020, RSC advances,
Wenyu Fu, and Yujianan Chen, and Kaidi Wang, and Aubryanna Hettinghouse, and Wenhuo Hu, and Jing-Quan Wang, and Zi-Ning Lei, and Zhe-Sheng Chen, and Kenneth A Stapleford, and Chuan-Ju Liu
Insilico drug repurposing using FDA approved drugs against Membrane protein of SARS-CoV-2.
June 2021, Journal of pharmaceutical sciences,
Wenyu Fu, and Yujianan Chen, and Kaidi Wang, and Aubryanna Hettinghouse, and Wenhuo Hu, and Jing-Quan Wang, and Zi-Ning Lei, and Zhe-Sheng Chen, and Kenneth A Stapleford, and Chuan-Ju Liu
Virtual screening FDA approved drugs against multiple targets of SARS-CoV-2.
May 2021, Clinical and translational science,
Wenyu Fu, and Yujianan Chen, and Kaidi Wang, and Aubryanna Hettinghouse, and Wenhuo Hu, and Jing-Quan Wang, and Zi-Ning Lei, and Zhe-Sheng Chen, and Kenneth A Stapleford, and Chuan-Ju Liu
Evaluations of FDA-approved drugs targeting 3CLP of SARS-CoV-2 employing a repurposing strategy.
August 2022, Combinatorial chemistry & high throughput screening,
Wenyu Fu, and Yujianan Chen, and Kaidi Wang, and Aubryanna Hettinghouse, and Wenhuo Hu, and Jing-Quan Wang, and Zi-Ning Lei, and Zhe-Sheng Chen, and Kenneth A Stapleford, and Chuan-Ju Liu
Structural insights into the SARS-CoV-2 Omicron RBD-ACE2 interaction.
June 2022, Cell research,
Copied contents to your clipboard!